
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.
The CPRD bibliography is updated on a monthly basis (last updated 4 December 2019) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 3MB, 193 pages)
,
“Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy”, Diabetes Care, vol. 41, pp. 2330-2338, 2018.
, “Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study”, Bmj, vol. 363, p. k4880, 2018.
, “Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus”, JAMA Intern Med, vol. 176, pp. 1474-1481, 2016.
, “Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink”, Bmj, vol. 355, p. i5340, 2016.
, “Pioglitazone use and risk of bladder cancer: population based cohort study”, Bmj, vol. 352, p. i1541, 2016.
, “The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death”, Can J Diabetes, vol. 39, pp. 383-9, 2015.
, “Incretin-based drugs and the risk of congestive heart failure”, Diabetes Care, vol. 38, pp. 277-84, 2015.
, “Metformin and low levels of thyroid-stimulating hormone in patients with type 2 diabetes mellitus”, Cmaj, vol. 186, pp. 1138-45, 2014.
,